skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New advances in the treatment of gout: review of pegloticase

Review

(2790) Views  (1203) Full article downloads

Authors: Mattheus K Reinders, Tim L Th A Jansen

Published Date October 2010 Volume 2010:6 Pages 543 - 550
DOI: http://dx.doi.org/10.2147/TCRM.S6043

Mattheus K Reinders1, Tim L Th A Jansen2
1Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Department of Rheumatology, University Medical Centre St. Radboud, Nijmegen, The Netherlands

Abstract: Treatment-failure gout (TFG) affects approximately 50,000 patients or about 1% of the overall population of patients with gout in the United States of America. The severity of TFG is manifested by frequent acute attacks of disabling arthritis, chronic deforming joint disease, destructive masses of urate crystals (tophi), progressive physical disability, and poor health-related quality of life. Pegloticase (Krystexxa®; Savient Pharmaceuticals, Inc), a novel PEGylated urate oxidase (uricase) enzyme, has been resubmitted for US Food and Drug Administration approval. In a 6-month, placebo-controlled clinical trial, 8 mg of pegloticase for every 2 weeks induced a lytic decrease of serum urate (sUr) concentrations, leading to dissolution of tophi in 40% of patients at final visit. However, 58% were nonresponders to the defined target sUr of 0.36 mmol/L (80% were nonresponders during months 3 and 6), possibly due to antibody formation. Also, 26%–31% experienced infusion reactions (IRs) and 77% suffered from gout flares. Although long-term data are awaited, an anti-inflammatory strategy, eg, based on glucocorticosteroids, is needed to prevent pegloticase antibody formation leading to IRs and diminished or shortened efficacy, and might also prevent gout flares. According to the current clinical data, pegloticase might have an important role as a (bridging) treatment in sUr-responsive patients for tophi clearance in severe chronic refractory gout.

Keywords: pegloticase, hyperuricemia, gout, pharmacotherapy, PEG-uricase




 

Other articles by Dr Mark Reinders



Readers of this article also read:

Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
Gout disease-specific quality of life and the association with gout characteristics
Treatment of Cushing disease: overview and recent findings
New and improved strategies for the treatment of gout
The role of the NLRP3 inflammasome in gout
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
The epidemiology and treatment of gout